glp 1 resistance GLP-1R as a potential link between diabetes and Alzheimer's disease One in 10 people may

Table 14

Drug patents last 20 years, but that time frame includes the many years it takes to test a drug before its brought to market

Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications primarily prescribed for type 2 diabetes management and, in some formulations, for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

Peptides occupy a fascinating middle ground between small molecules and biologics they can be engineered with highly tunable pharmacokinetic and pharmacodynamic profiles, while offering advantages like lower immunogenicity, better tissue penetration, and reduced manufacturing costs compared to antibodies or proteins

So, lets sit down and have an honest conversation about your real options, what the science actually says, and what might work best for you

Despite the range of brand names, the market is dominated by just two companies: Eli Lilly in the U.S